Healthcare ranking
Top 25 solid tumor clinical trial sponsors 2026
Jiangsu Hengrui Pharmaceuticals started the most solid tumor clinical trials as lead sponsor between November 2023 and October 2026, with 52 trials. The list ranks companies worldwide by the number of new interventional trials they lead in this area.
Top 10 at a glance
The full list
| Rank | Company | Headquarters | new industry-sponsored clinical trials (trials) |
|---|---|---|---|
| 1 | Jiangsu Hengrui Pharmaceuticals | China | 52 |
| 2 | Sichuan Baili Pharmaceutical (Biokin) | China | 37 |
| 3 | BeOne Medicines (BeiGene) | Switzerland | 19 |
| 4 | Qilu Pharmaceutical | China | 17 |
| 5 | Hansoh Pharmaceutical | China | 16 |
| 6 | CSPC Pharmaceutical Group | China | 14 |
| 7 | AstraZeneca | United Kingdom | 13 |
| 8 | Bristol Myers Squibb | United States | 12 |
| 9 | Daiichi Sankyo | Japan | 11 |
| 10 | Kelun-Biotech | China | 10 |
| 11 | Akeso | China | 9 |
| 11 | Innovent Biologics | China | 9 |
| 11 | Merck KGaA | Germany | 9 |
| 11 | MediLink Therapeutics | China | 9 |
| 11 | Shanghai Henlius Biotech | China | 9 |
| 16 | Boehringer Ingelheim | Germany | 8 |
| 16 | Genmab | Denmark | 8 |
| 16 | Minghui Pharmaceutical | China | 8 |
| 19 | Hangzhou Zhongmei Huadong Pharmaceutical | China | 7 |
| 19 | Incyte | United States | 7 |
| 19 | Jiangsu Simcere Pharmaceutical | China | 7 |
| 19 | LaNova Medicines | China | 7 |
| 23 | Alphamab Oncology | China | 6 |
| 23 | Eli Lilly | United States | 6 |
| 23 | Gilead Sciences | United States | 6 |
| 23 | Haisco Pharmaceutical Group | China | 6 |
| 23 | BioNTech | Germany | 6 |
| 23 | Changchun GeneScience Pharmaceutical | China | 6 |
| 23 | Convalife | China | 6 |
| 23 | Exelixis | United States | 6 |
| 23 | Sinocelltech | China | 6 |
How this list is built
We counted interventional clinical trials with a company as lead sponsor and a start date from 1 November 2023 to 31 October 2026 that list solid tumor as a studied condition; withdrawn trials are not counted. Subsidiaries and name variants are merged into the parent company ("Jiangsu HengRui Medicine Co., Ltd." and "Suzhou Suncadia Biopharmaceuticals Co., Ltd." are counted as Jiangsu Hengrui Pharmaceuticals), and hospitals, universities and other non-company sponsors are left out. Companies with the same count share a rank, and all companies tied at the last place are shown.
Every position is set by the data alone, by the same rules for every company. Spotted something to update? Write to info@stratummarketresearch.com with the list and the line, and we correct it within two working days.
For ranked companies: a free badge
Ranked companies can show this badge on their website, in a press release or on LinkedIn at no cost. Pick your company, then copy the code.
Frequently asked questions
Who is number one in the solid tumor clinical trial sponsors ranking?
Jiangsu Hengrui Pharmaceuticals ranks first with 52 trials (November 2023 to October 2026).
How is this ranking calculated?
We counted interventional clinical trials with a company as lead sponsor and a start date from 1 November 2023 to 31 October 2026 that list solid tumor as a studied condition; withdrawn trials are not counted. Subsidiaries and name variants are merged into the parent company ("Jiangsu HengRui Medicine Co., Ltd." and "Suzhou Suncadia Biopharmaceuticals Co., Ltd." are counted as Jiangsu Hengrui Pharmaceuticals), and hospitals, universities and other non-company sponsors are left out. Companies with the same count share a rank, and all companies tied at the last place are shown.
Can a company pay to rank higher?
Positions come only from the counts described above, and inclusion is free. Every company is ranked by the same rules.
How often is the ranking updated?
Every list is recomputed each quarter from the latest public records, and the update date is printed on the page.
Can a ranked company use the badge?
Yes. Every ranked company can use the free web badge on this page on its website, in press releases and on social media.
Custom research
Looking for a specific market?
Tell us the market, the region and the decision you are making. We reply within one working day with a scope and a date.